BioSpace News Archive

BostonGene, a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G.

Starpax Biopharma Inc., a biopharmaceutical company developing a groundbreaking cancer treatment platform technology, is pleased to announce the promotion of Mrs. Andréanne Cyr to Vice President Finance.

Meilleur Technologies, Inc. announced a research collaboration agreement with the Young Blood Institute on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography scans to assess the status of amyloid plaque in the brain.

Icosavax, Inc. announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults.

ViroCell Biologics announces a new partnership with University College London to advance Professor Persis Amrolia’s innovative chimeric antigen receptor T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia.

ISA Pharmaceuticals B.V. announced positive anti-tumor response data with ISA101b, an HPV16 directed therapeutic cancer vaccine given in combination with Libtayo®, an anti-PD1 checkpoint inhibitor.

BioNxt Solutions Inc. is pleased to announce that it has received delivery of state-of-the-art coating and cutting equipment necessary for the buildout of commercial manufacturing capacity at its Vektor Pharma TF GmbH facility in Baden-Württemberg, Germany.

SOLASCURE Ltd, a biotechnology company developing a hydrogel containing tarumase, a recombinant enzyme derived from maggots, and which aims to accelerate wound debridement and contribute to wound bed preparation & healing, announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.

ADC Therapeutics SA announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory follicular lymphoma.

Allarity Therapeutics, Inc. today announced a transition in its leadership.